Molecular screening for breast cancer prevention, early detection, and treatment planning: combining biomarkers from DNA, RNA, and protein.
The completion of the human genome project, along with the ancillary technologies derived from this effort, provides the ability to comprehensively analyze patient tumors as well as the individual patient's own genetic make-up at the DNA, RNA, and protein level. As a result, novel molecular screening techniques have the potential to push the boundaries of detection to even smaller tumors and also to allow accurate risk assessment, cancer prevention, and treatment planning in individual women. This review focuses on advances over the past 2 years in the use of molecular signatures and circulating tumor cells for early breast cancer detection and for prediction of response to therapy.
Stemke-Hale
Katherine
K
Kleberg Center for Molecular Markers, Department of Molecular Therapeutics - Unit 950, University of Texas M.D. Anderson Cancer Center, Houston TX 77054, USA.
Hennessy
Bryan
B
Mills
Gordon B
GB
Mitra
Rahul
R
D014408:Biomarkers, Tumor / Q000032:analysis / Q000097:blood; D001943:Breast Neoplasms / Q000175:diagnosis* / Q000517:prevention & control / Q000628:therapy*; D019496:Cancer Vaccines / Q000627:therapeutic use; D002277:Carcinoma / Q000175:diagnosis* / Q000517:prevention & control / Q000628:therapy*; D004247:DNA / Q000032:analysis; D042241:Early Diagnosis; D005260:Female; D020022:Genetic Predisposition to Disease; D006801:Humans; D025202:Molecular Diagnostic Techniques / Q000379:methods*; D009360:Neoplastic Cells, Circulating / Q000473:pathology; D010347:Patient Care Planning; D011379:Prognosis; D011506:Proteins / Q000032:analysis; D012313:RNA / Q000032:analysis; D012680:Sensitivity and Specificity
D014408:Biomarkers, Tumor; D019496:Cancer Vaccines; D011506:Proteins; D012313:RNA; D004247:DNA